Payment overview · 2025
General Payments
$1,337.35
29 reported records · 13 companies
Healthcare provider profile · identity verified
Jill Kristen Couch, DO
Allopathic & Osteopathic Physicians|Hospitalist · NORTON, VA · NPI 1972561702
Verified facts
What the public records show
CMS Open Payments records show Jill Kristen Couch, DO received $1,337.35 in general payments during 2025 across 29 reported records.
Alkermes, Inc. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $247.44 | 18.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $174.41 | 13.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.15 | 12.6% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $160.83 | 12.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $160.49 | 12.0% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $125.00 | 9.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $111.14 | 8.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $86.48 | 6.5% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.51 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.87 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.41 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.38 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.24 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,337.35 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $174.41 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $160.83 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $141.02 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $122.44 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $122.44 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $111.14 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $86.48 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $52.73 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.51 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $27.13 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
124 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 642 | 167 |
| Lisinopril | Lisinopril | 597 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 152 |
| Omeprazole | Omeprazole | 514 | 151 |
| Furosemide | Furosemide | 486 | 148 |
| Pantoprazole Sodium | Pantoprazole Sodium | 457 | 145 |
| Losartan Potassium | Losartan Potassium | 437 | 137 |
| Metoprolol Tartrate | Metoprolol Tartrate | 437 | 122 |
| Montelukast Sodium | Montelukast Sodium | 431 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 420 | 120 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 411 | 82 |
| Metformin Hcl | Metformin Hcl | 372 | 105 |
| Gabapentin | Gabapentin | 333 | 61 |
| Cefdinir | Cefdinir | 298 | 196 |
| Famotidine | Famotidine | 279 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 261 | 92 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 260 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 219 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 64 |
| Trazodone Hcl | Trazodone Hcl | 216 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 210 | 55 |
| Carvedilol | Carvedilol | 198 | 57 |
| Eliquis | Apixaban | 196 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 56 |
| Simvastatin | Simvastatin | 189 | 51 |
| Ozempic | Semaglutide | 187 | 35 |
| Glipizide | Glipizide | 183 | 50 |
| Atenolol | Atenolol | 170 | 43 |
| Alendronate Sodium | Alendronate Sodium | 164 | 61 |
| Ondansetron Hcl | Ondansetron Hcl | 155 | 50 |
| Prednisone | Prednisone | 155 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 62 |
| Spironolactone | Spironolactone | 142 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 133 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 133 | 33 |
| Meloxicam | Meloxicam | 133 | 50 |
| Sertraline Hcl | Sertraline Hcl | 132 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 39 |
| Azithromycin | Azithromycin | 126 | 103 |
| Mounjaro | Tirzepatide | 124 | 23 |
| Potassium Chloride | Potassium Chloride | 123 | 37 |
| Tramadol Hcl | Tramadol Hcl | 120 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 34 |
| Lovastatin | Lovastatin | 114 | 30 |
| Buspirone Hcl | Buspirone Hcl | 112 | 37 |
| Propranolol Hcl | Propranolol Hcl | 112 | 26 |
| Sucralfate | Sucralfate | 111 | 44 |
| Nystatin | Nystatin | 110 | 58 |
| Allopurinol | Allopurinol | 104 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 36 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 98 | 29 |
| Alprazolam | Alprazolam | 92 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 15 |
| Ibuprofen | Ibuprofen | 91 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 21 |
| Trulicity | Dulaglutide | 77 | 13 |
| Baclofen | Baclofen | 75 | 21 |
| Jardiance | Empagliflozin | 73 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 21 |
| Metformin Hcl Er | Metformin Hcl | 70 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 20 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 68 | 18 |
| Meclizine Hcl | Meclizine Hcl | 67 | 21 |
| Topiramate | Topiramate | 67 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 22 |
| Aripiprazole | Aripiprazole | 65 | 22 |
| Ezetimibe | Ezetimibe | 65 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 16 |
| Januvia | Sitagliptin Phosphate | 62 | 18 |
| Amoxicillin | Amoxicillin | 60 | 53 |
| Lorazepam | Lorazepam | 60 | 12 |
| Promethazine Hcl | Promethazine Hcl | 58 | 15 |
| Finasteride | Finasteride | 57 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 52 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 43 |
| Diazepam | Diazepam | 49 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 49 | 45 |
| Fluconazole | Fluconazole | 48 | 33 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 27 |
| Donepezil Hcl | Donepezil Hcl | 46 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 37 |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Lidocaine | Lidocaine | 41 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Linzess | Linaclotide | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Glimepiride | Glimepiride | 34 | 11 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 14 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 24 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 22 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Savella | Milnacipran Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Tresiba | Insulin Degludec | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,337.35 · 29 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, ARISTADA, ARISTADA INITIO, Auvelity, BREZTRI, CAPLYTA, COBENFY, FANAPT, GEMTESA, LYBALVI, LifeVest, REXULTI, TRELEGY ELLIPTA, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error